AllRock Bio Initiates Phase 2a Trial of ROC-101 for Pulmonary Hypertension Treatment AllRock Bio has commenced its Phase 2a ROCSTAR trial, administering ROC-101 to patients with pulmonary hypertension to assess safety and efficacy combined with standard therapies.

AllRock Bio Initiates Phase 2a Trial of ROC-101 for Pulmonary Hypertension Treatment #USA #Natick #Pulmonary_Hypertension #AllRock_Bio #ROC-101

phaware® Unveils Heart Works Mobile App to Empower Pulmonary Hypertension Patients In celebration of Rare Disease Day, phaware global association introduces the Heart Works app designed to support the pulmonary hypertension community through connection and education.

phaware® Unveils Heart Works Mobile App to Empower Pulmonary Hypertension Patients #USA #Los_Angeles #Pulmonary_Hypertension #phaware #Heart_Works

Cereno Scientific Expands Development of CS014 to Target Pulmonary Hypertension in Lung Disease Cereno Scientific is broadening its clinical focus for CS014 to target pulmonary hypertension linked to interstitial lung disease, addressing significant unmet medical needs.

Cereno Scientific Expands Development of CS014 to Target Pulmonary Hypertension in Lung Disease #Sweden #Gothenburg #Pulmonary_Hypertension #Cereno_Scientific #CS014

Cereno Scientific's CS1 Receives FDA Approval for Global Phase IIb Trial in PAH Indication Cereno Scientific celebrates FDA clearance to commence a Phase IIb trial for CS1, a potential treatment for pulmonary arterial hypertension. The trial aims to improve patient outcomes.

Cereno Scientific's CS1 Receives FDA Approval for Global Phase IIb Trial in PAH Indication #Gothenburg #Pulmonary_Hypertension #Cereno_Scientific #CS1

American Lung Association Unveils New Support Program for Pulmonary Hypertension Awareness The American Lung Association has launched a free program to educate families about pulmonary arterial hypertension, aiming to improve diagnosis and management.

American Lung Association Unveils New Support Program for Pulmonary Hypertension Awareness #United_States #Chicago #American_Lung_Association #Health_Awareness #Pulmonary_Hypertension

AllRock Bio Secures $50 Million in Series A Funding to Propel Innovative Pulmonary Hypertension Treatment AllRock Bio Inc. has successfully raised $50 million to advance ROC-101, its lead clinical candidate aimed at treating pulmonary hypertension and interstitial lung disease.

AllRock Bio Secures $50 Million in Series A Funding to Propel Innovative Pulmonary Hypertension Treatment #United_States #Natick #Pulmonary_Hypertension #AllRock_Bio #ROC-101

Pulnovo Medical Achieves Significant Milestone with Two IDE Approvals for PADN Clinical Trials Pulnovo Medical has received IDE approvals for the PADN system, enabling crucial clinical trials for pulmonary hypertension with full CMS coverage.

Pulnovo Medical Achieves Significant Milestone with Two IDE Approvals for PADN Clinical Trials #Shanghai #None #Pulmonary_Hypertension #Pulnovo_Medical #PADN_System

Synhale Therapeutics Moves Forward with Acquisition of Telaglenastat for Treating Pulmonary Hypertension Synhale Therapeutics has acquired Telaglenastat, a key move to enhance the company's clinical programs for pulmonary hypertension, targeting unmet patient needs.

Synhale Therapeutics Moves Forward with Acquisition of Telaglenastat for Treating Pulmonary Hypertension #None #Boston #Pulmonary_Hypertension #Synhale_Therapeutics #Telaglenastat

Eko Health Unveils Groundbreaking AI Study for Detecting Pulmonary Hypertension Early Eko Health has published a pivotal research study showcasing AI's potential in the early detection of pulmonary hypertension, marking a significant advancement in cardiopulmonary health.

Eko Health Unveils Groundbreaking AI Study for Detecting Pulmonary Hypertension Early #USA #San_Francisco #AI_Detection #Eko_Health #Pulmonary_Hypertension